Allogene Therapeutics Presents Positive Phase 1 Data on ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma at the 2021 Annual Meeting of the American Society of Clinical Oncology

NEXT STORY
TRACON Pharmaceuticals Presents Data from a Phase 1 Study of Uliledlimab (TJ004309) and Tecentriq® (Atezolizumab) at the American Society of Clinical Oncology Virtual Annual Meeting
PREV STORY
Immunoassay Market Worth $46.5 Billion by 2028, Growing at a CAGR of 7.5% From 2021- Exclusive Report by Meticulous Research®
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

DUBLIN, Ireland, May 30, 2017 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), today announced ...

author_avatar
NASDAQ Market News

Onconova Therapeutics Announces Plan for Expanding Rigosertib Clinical Trials for Patients with Myelodysplastic Syndromes (MDS) to South America with Pint Pharma

Pint Pharma to facilitate expansion of Phase 3 INSPIRE trial to Argentina, Chile, and ...

author_avatar
NASDAQ Market News

Orion to renew operating model of its laboratories

ORION CORPORATION                               PRESS RELEASE                4 JANUARY 2018 at 11.15         Orion to renew operating ...

author_avatar
NASDAQ Market News